↓ Skip to main content

Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study

Overview of attention for article published in BMC Complementary Medicine and Therapies, January 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
4 news outlets
twitter
41 X users
patent
2 patents
facebook
10 Facebook pages
video
4 YouTube creators

Citations

dimensions_citation
144 Dimensions

Readers on

mendeley
356 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study
Published in
BMC Complementary Medicine and Therapies, January 2018
DOI 10.1186/s12906-017-2062-z
Pubmed ID
Authors

Armine Haroyan, Vahan Mukuchyan, Nana Mkrtchyan, Naira Minasyan, Srbuhi Gasparyan, Aida Sargsyan, Mikael Narimanyan, Areg Hovhannisyan

Abstract

The aim of this clinical trial was to assess the efficacy and safety of curcuminoid complex extract from turmeric rhizome with turmeric volatile oil (CuraMed®) and its combination with boswellic acid extract from Indian frankincense root (Curamin®) vs placebo for the treatment of 40- to 70-year-old patients with osteoarthritis (OA). The effects of CuraMed® 500-mg capsules (333 mg curcuminoids) and Curamin® 500-mg capsules (350 mg curcuminoids and 150 mg boswellic acid) taken orally three times a day for 12 weeks in 201 patients was investigated in a three-arm, parallel-group, randomized, double-blinded, placebo-controlled trial. Primary outcome efficacy measures included OA physical function performance-based tests, the WOMAC recommended index of joint pain, morning stiffness, limitations of physical function, and the patients' global assessment of disease severity. Favorable effects of both preparations compared to placebo were observed after only 3 months of continuous treatment. A significant effect of Curamin® compared to placebo was observed both in physical performance tests and the WOMAC joint pain index, while superior efficacy of CuraMed vs placebo was observed only in physical performance tests. The effect size compared to placebo was comparable for both treatment groups but was superior in the Curamin® group. The treatments were well tolerated. Twelve-week use of curcumin complex or its combination with boswellic acid reduces pain-related symptoms in patients with OA. Curcumin in combination with boswellic acid is more effective. Combining Curcuma longa and Boswellia serrata extracts in Curamin® increases the efficacy of OA treatment presumably due to synergistic effects of curcumin and boswellic acid. This trial is registered at the database www.clinicaltrials.gov . https://clinicaltrials.gov/ct2/show/NCT02390349?term=EuroPharma&rank=1 . Study registration number: NCT02390349 .

X Demographics

X Demographics

The data shown below were collected from the profiles of 41 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 356 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 356 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 60 17%
Student > Master 41 12%
Researcher 27 8%
Student > Doctoral Student 23 6%
Student > Ph. D. Student 21 6%
Other 55 15%
Unknown 129 36%
Readers by discipline Count As %
Medicine and Dentistry 60 17%
Nursing and Health Professions 42 12%
Biochemistry, Genetics and Molecular Biology 31 9%
Pharmacology, Toxicology and Pharmaceutical Science 31 9%
Agricultural and Biological Sciences 12 3%
Other 44 12%
Unknown 136 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 70. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 March 2024.
All research outputs
#615,548
of 25,523,622 outputs
Outputs from BMC Complementary Medicine and Therapies
#80
of 3,967 outputs
Outputs of similar age
#14,242
of 451,773 outputs
Outputs of similar age from BMC Complementary Medicine and Therapies
#5
of 124 outputs
Altmetric has tracked 25,523,622 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,967 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,773 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 124 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.